Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 16/20 | 0.56 |
| ▸ | NTSR1 | P30989 | 16/20 | 0.56 |
| ▸ | SORT1 | Q99523 | 14/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8418325 | 0.97 | NTSR2 (0.55) | NTSR2NTSR1SORT1OPRK1OPRM1 | |
| SCHEMBL8225148 | 0.96 | NTSR2 (0.53) | NTSR2NTSR1SORT1OPRK1OPRM1 | |
| SCHEMBL8414624 | 0.93 | NTSR2 (0.51) | NTSR2NTSR1SORT1OPRK1OPRM1 | |
| SCHEMBL29494697 | 0.80 | NTSR2 (0.63) | NTSR2NTSR1SORT1OPRK1 | |
| SCHEMBL8225161 | 0.79 | CALCRL (0.44) | — | |
| SCHEMBL29478299 | 0.78 | NTSR2 (0.61) | NTSR2NTSR1 | |
| Kifgslafl SCHEMBL29356758 | 0.76 | BACE1 (0.57) | NTSR2NTSR1OPRK1OPRM1OPRD1 | |
| SCHEMBL30799723 | 0.76 | OPRK1 (0.57) | NTSR2NTSR1OPRK1OPRM1OPRD1 | |
| SCHEMBL29447812 | 0.76 | NTSR2 (0.69) | NTSR2NTSR1SORT1OPRK1 | |
| SCHEMBL38652231 | 0.76 | NTSR2 (0.54) | NTSR2NTSR1SORT1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511039-B2 | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INCORPORATED (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | SERPINB1, SERPINE1, SERPINA2 | NTSR2 4267/4885NTSR1 3582/4885SORT1 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.